Sam Shrivastava
Company: Venn Therapeutics
Job title: Chairman & CEO
Seminars:
Integrin αvβ8-Expressing Tumor Cells Serve as a Platform for TGF-ß Activation 1:00 pm
This discovery offers a promising novel target to safely and effectively overcome TGF-β-driven immuno-suppression in a variety of tumor types. • Venn Therapeutics is driven by a paradigm-shifting discovery by Dr. Stephen Nishimura on how transforming growth factor-beta (TGF-β) is activated by integrin αvβ8, published in Cell in January 2020. Dr. Nishimura’s paper showed that…Read more
day: Day One